01 1Amphastar Nanjing Pharmaceuticals, Inc.
01 1Insulin Glargine
01 1U.S.A
NDC Package Code : 52221-125
Start Marketing Date : 2020-08-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Insulin Glargine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Insulin Glargine, including repackagers and relabelers. The FDA regulates Insulin Glargine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Insulin Glargine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Insulin Glargine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Insulin Glargine supplier is an individual or a company that provides Insulin Glargine active pharmaceutical ingredient (API) or Insulin Glargine finished formulations upon request. The Insulin Glargine suppliers may include Insulin Glargine API manufacturers, exporters, distributors and traders.
click here to find a list of Insulin Glargine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Insulin Glargine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Insulin Glargine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Insulin Glargine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Insulin Glargine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Insulin Glargine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Insulin Glargine suppliers with NDC on PharmaCompass.
We have 1 companies offering Insulin Glargine
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
